Pemigatinib
Tier C — Watch / tradePemigatinib · all drugs expiring in 2032 →
Targets：FGFR1, FGFR2, FGFR3
Brand：Pemazyre
Indications (approved)：Myeloma, Lymphoma, Bile duct cancer, Cholangiocarcinoma, Biliary tract cancer
Regional status
Synthetic routes & intermediates2 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| PEMIGA-001 | 271-63-6Available | 1H-pyrrolo[2,3-b]pyridine |
| PEMIGA-002 | 504440-63-5 | 1H-pyrrolo[2,3-b]pyridine 7-oxide |
| PEMIGA-003 | 55052-28-3 | 4-chloro-1H-pyrrolo[2,3-b]pyridine |
| PEMIGA-004 | 651744-48-8 | 4-chloro-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine |
| PEMIGA-005 | 958230-19-8 | 4-chloro-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde |
| PEMIGA-006 | 1032815-07-8 | 4-chloro-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde |
| PEMIGA-007 | 1032815-08-9 | 4-chloro-5-(1,3-dioxolan-2-yl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine |
| PEMIGA-008 | 4394-85-8 | morpholine-4-carbaldehyde |
| PEMIGA-009 | 2382664-55-1 | 4-chloro-5-(1,3-dioxolan-2-yl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-2-carbaldehyde |
| PEMIGA-010 | 2382664-58-4 | 4-((4-chloro-5-(1,3-dioxolan-2-yl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)methyl)morpholine |
| PEMIGA-011 | 2382664-60-8 | 4-chloro-2-(morpholinomethyl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde |
| PEMIGA-012 | 651734-54-2 | 2,6-difluoro-3,5-dimethoxyaniline |
| PEMIGA-013 | 2382664-61-9 | N-((4-chloro-2-(morpholinomethyl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)methyl)-2,6-difluoro-3,5-dimethoxyaniline |
| PEMIGA-014 | 109-90-0 | isocyanatoethane |
| PEMIGA-015 | 2382664-64-2 | 1-((4-chloro-2-(morpholinomethyl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)methyl)-1-(2,6-difluoro-3,5-dimethoxyphenyl)-3-ethylurea |
| PEMIGA-016 | 1513860-02-0 | 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholinomethyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one |
| PEMIGA-017 | 602-94-8 | 2,3,4,5,6-pentafluorobenzoic acid |
| PEMIGA-018 | 36629-42-2 | methyl 2,3,4,5,6-pentafluorobenzoate |
| PEMIGA-019 | 122590-82-3 | methyl 4-(benzylamino)-2,3,5,6-tetrafluorobenzoate |
| PEMIGA-020 | 651734-52-0 | 4-(benzylamino)-3,5-difluoro-2,6-dimethoxybenzoic acid |
| PEMIGA-021 | 651734-53-1 | N-benzyl-2,6-difluoro-3,5-dimethoxyaniline |
| Pemigatinib | 1513857-77-6 | - |
| Code | CAS No. | Intermediate |
|---|---|---|
| PEMIGA-003 | 55052-28-3 | 4-chloro-1H-pyrrolo[2,3-b]pyridine |
| PEMIGA-004 | 651744-48-8 | 4-chloro-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine |
| PEMIGA-005 | 958230-19-8 | 4-chloro-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde |
| PEMIGA-022 | 915403-16-6 | 4-(ethylamino)-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde |
| PEMIGA-012 | 651734-54-2 | 2,6-difluoro-3,5-dimethoxyaniline |
| PEMIGA-023 | 1513859-26-1 | 5-(((2,6-difluoro-3,5-dimethoxyphenyl)amino)methyl)-N-ethyl-1H-pyrrolo[2,3-b]pyridin-4-amine |
| PEMIGA-024 | 1513857-72-1 | 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one |
| PEMIGA-025 | 1513860-01-9 | 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one |
| PEMIGA-026 | 1593816-94-4 | 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-2-oxo-7-(phenylsulfonyl)-2,3,4,7-tetrahydro-1H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidine-8-carbaldehyde |
| PEMIGA-027 | 110-91-8Available | morpholine |
| PEMIGA-016 | 1513860-02-0 | 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholinomethyl)-7-(phenylsulfonyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one |
| Pemigatinib | 1513857-77-6 | - |
Frequently asked questions
What are the approved indications of Pemigatinib?
Approved indications include: Myeloma, Lymphoma, Bile duct cancer, Cholangiocarcinoma, Biliary tract cancer.
When does the Pemigatinib patent expire?
Based on public sources, the Pemigatinib patent expires in 2032.
How many synthesis routes are recorded for Pemigatinib?
2 synthesis routes are recorded; the shortest is 7 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Pemigatinib intermediates?
2 intermediate CAS of Pemigatinib are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Pemigatinib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29